Ameritas Investment Partners, Inc. Summit Therapeutics Inc. Transaction History
Ameritas Investment Partners, Inc.
- $2.98 Billion
- Q3 2024
A detailed history of Ameritas Investment Partners, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 8,577 shares of SMMT stock, worth $157,387. This represents 0.01% of its overall portfolio holdings.
Number of Shares
8,577
Previous 8,577
-0.0%
Holding current value
$157,387
Previous $66,000
183.33%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$448 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$201 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$145 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$99.8 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$63.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.69B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...